

Int'l Appl. No. : PCT/JP2004/000332  
Int'l Filing Date : January 16, 2004

### AMENDMENTS TO THE CLAIMS

**Please amend the Claim Form and Claim as follows. Insertions are shown underlined while deletions are ~~struck through~~.**

1 (original): An expired dendritic cell having characteristics of the following (E1) to (E3):  
(E1) not shifting into a mature type due to an action of a natural immune stimulant or a permanent immune potentiator;  
(E2) having the same shape as immature DC; and  
(E3) expressing IL-10.

2 (original): The expired dendritic cell according to claim 1 wherein said dendritic cell is a human dendritic cell.

3 (original): The human expired dendritic cell according to claim 2 having the following characteristics:  
(E1') not shifting into a mature type due to an action of LPS and anti-CD40 monoclonal antibody;  
(E2) having the same shape as immature DC; and  
(E3) expressing IL-10.

4 (original): The human expired dendritic cell according to claim 3 further having the following characteristics:  
(E4) having an expression level of CD80 nearly equivalent to that on the immature DC; and/or  
(E5) having an expression level of CD83 nearly equivalent to that on the immature DC.

5 (original): The human expired dendritic cell according to claim 4 further having at least one of the following characteristics:  
(E6) having a phagocytic activity for microbeads nearly equivalent to that of the immature dendritic cells;  
(E7) expressing MHC class I at a high level;  
(E8) not activating unreacted T cells in the presence of an antigenic peptide; and  
(E9) expressing TLR4/MD2 at lower level than the immature DC.

6 (original): Permanently activated dendritic cells having the following characteristics:  
(M2-1) having projecting dendrites and forming aggregation clusters;  
(M2-2) being capable of activating unreacted cytotoxic T cells (CTL);  
(M2-3) having stable properties under the action of anti-CD40 monoclonal antibody; and  
(M2-4) showing a high expression level of at least one member selected from the group consisting of CD80, CD83 and CD86.

7 (original): The permanently activated dendritic cells according to claim 6 wherein said dendritic cells are cells derived from human, having the following characteristics:  
(M2-1) having projecting dendrites and forming aggregation clusters;  
(M2-2) being capable of activating unreacted cytotoxic T cells (CTL);  
(M2-3) having stable properties under the action of anti-CD40 monoclonal antibody; and  
(M2-4') expressing CD80 and CD83 at high levels.

8 (original): The permanently activated dendritic cell according to claim 7 further having at least one of the following characteristics:  
(M2-5) expressing FcγR at a low level (FcγR<sup>low</sup>);  
(M2-6) expressing MHC-I at a high level (MHC-I<sup>high</sup>);  
(M2-7) expressing MHC-II at a high level (MHC-II<sup>high</sup>); and  
(M2-8) expressing IL-12 p40 at a high level.

9 (original): A method for preparing expired dendritic cells (expired DC) comprising a step of activating immature dendritic cells with a natural immune stimulant to induce transiently activated mature dendritic cells (M1DC), and a step of culturing the M1DC in the absence of a permanent immune potentiator.

10 (original): A method for preparing permanently activated mature dendritic cells (M2DC) comprising a step of treating immature dendritic cells with a permanent immune potentiator.

11 (original): A method for preparing permanently activated mature dendritic cells (M2DC) comprising a step of activating immature dendritic cells with a natural immune stimulant to

**Int'l Appl. No. : PCT/JP2004/000332**  
**Int'l Filing Date : January 16, 2004**

induce transiently activated mature dendritic cells (M1DC), and a step of culturing the M1DC in the presence of a permanent immune potentiator.

12 (original): A method for preparing transiently activated mature dendritic cells (M1DC) characterized by treating immature dendritic cells with a natural immune stimulant.

13 (currently amended): An anti-cancer agent wherein the human permanently activated dendritic cell (M2DC) according to claim 7 ~~or 8 or the human M2DC prepared by the method according to claim 10 or 11~~ is an active ingredient.

14 (currently amended): An anti-pathogen agent wherein the human permanently activated dendritic cell (M2DC) according to claim 7 ~~or 8 or the human M2DC prepared by the method according to claim 10 or 11~~ is an active ingredient.

15 (currently amended): An immunosuppressive drug wherein the expired dendritic cell according to claims 1 to 5 ~~or the expired dendritic cell obtained by the method according to claim 9~~ is an active ingredient.

16 (currently amended): A method for treating cancer characterized in that the human permanently activated dendritic cell (M2DC) according to claim 7 ~~or 8 or the human M2DC prepared by the method according to claim 10 or 11~~ is administered to a human patient with cancer.

17 (currently amended): A method for transplantation where an immunological rejection is inhibited, comprising introduction of human expired dendritic cells according to claims 2 to 5 ~~or human expired dendritic cells obtained by the method according to claim 9~~ derived from a human transplantation donor into a human recipient, and then introduction of an organ or a tissue of the human transplantation donor into the human recipient.

18 (original): The method according to claim 17 wherein said organ or tissue is bone marrow.